Exkivity is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 2 US drug patents filed in 2021 out of which none have expired yet. Exkivity's patents will be open to challenges from 15 September, 2025. Based on its patents and exclusivities, its generic launch date is estimated to be May 13, 2035. Details of Exkivity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10227342 | Heteroaryl compounds for kinase inhibition |
May, 2035
(10 years from now) | Active |
| US9796712 | Heteroaryl compounds for kinase inhibition |
May, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Exkivity's patents.
Latest Legal Activities on Exkivity's Patents
Given below is the list of recent legal activities going on the following patents of Exkivity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Letter from FDA or Dept of Agriculture re PTE application | 15 Jul, 2024 | US9796712 |
| Letter from FDA or Dept of Agriculture re PTE application | 15 Jul, 2024 | US10227342 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US10227342 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US9796712 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9796712 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US10227342 |
| Second letter to regulating agency to determine regulatory review period | 31 Jan, 2023 | US10227342 |
| Second letter to regulating agency to determine regulatory review period | 31 Jan, 2023 | US9796712 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2022 | US9796712 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Aug, 2022 | US10227342 |
FDA has granted several exclusivities to Exkivity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Exkivity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Exkivity.
Exclusivity Information
Exkivity holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Exkivity's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2026 |
| Orphan Drug Exclusivity(ODE-374) | Sep 15, 2028 |
US patents provide insights into the exclusivity only within the United States, but Exkivity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Exkivity's family patents as well as insights into ongoing legal events on those patents.
Exkivity's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Exkivity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 13, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Exkivity Generics:
There are no approved generic versions for Exkivity as of now.
About Exkivity
Exkivity is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy. Exkivity uses Mobocertinib Succinate as an active ingredient. Exkivity was launched by Takeda Pharms Usa in 2021.
Approval Date:
Exkivity was approved by FDA for market use on 15 September, 2021.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Exkivity is 15 September, 2021, its NCE-1 date is estimated to be 15 September, 2025.
Active Ingredient:
Exkivity uses Mobocertinib Succinate as the active ingredient. Check out other Drugs and Companies using Mobocertinib Succinate ingredient
Treatment:
Exkivity is used for treating non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy.
Dosage:
Exkivity is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MG BASE | CAPSULE | Discontinued | ORAL |